Why Is AstraZeneca Plc Up Today?

AstraZeneca Plc (LSE:AZN) shares rose 0.99% to 14,034.0p today, a gain of 138.0p. The pharmaceutical group is the largest company by weighting in the FTSE 100 at 8.10%, and it remains in focus following its third-quarter results.

For the first nine months of 2026, total Revenue was US$46.9 billion, up 7% at constant exchange rates, while core Earnings Per Share rose 14% to US$8.00.

About AstraZeneca Plc

AstraZeneca Plc is a global science-led biopharmaceutical company headquartered in Cambridge, UK. It discovers, develops and supplies prescription medicines in oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare disease.

Its medicines reach patients in more than 100 countries, and its pipeline spans small molecules, Biologics and newer modalities. LSE:AZN has a Market Capitalisation of about £215.5 billion, placing it among the most valuable companies in the UK market.

Third-Quarter and Nine-Month Results

Third-quarter revenue was US$16.2 billion, up 7% at constant exchange rates, and third-quarter core earnings per share increased 19% to US$2.79. For the nine months, core operating profit rose 14% to US$16.4 billion.

These results show that revenue growth is converting into higher profit, helped by operational efficiency and a favourable product mix.

Oncology Leads Growth

Oncology revenue was US$21.9 billion in the nine months, up 16% at constant exchange rates, and now represents 47% of total revenue. It is the group's largest therapy area and the main driver of growth.

Continued uptake of established cancer medicines, together with new indications and launches, has supported Demand across major markets.

BioPharmaceuticals and Rare Disease

BioPharmaceuticals revenue was US$16.7 billion, or 36% of the total, reflecting a broad portfolio in cardiovascular, renal, metabolic and respiratory care. Rare Disease revenue rose 11% to US$7.5 billion, representing 16% of total revenue.

Together these areas diversify the group's income and give it multiple avenues for future growth.

Pipeline Progress

AstraZeneca reported 12 positive Phase III readouts in the year to date, with combined peak-year revenue potential well in excess of US$10 billion. Management highlighted further readouts due in 2027 with potential in excess of US$20 billion.

A deep late-stage pipeline is the foundation for the group's long-term ambitions, and the company continues to invest across several modalities.

2026 Guidance

Full-year guidance was reconfirmed. Total revenue is expected to increase by a mid-to-high single-digit percentage at constant exchange rates, and core earnings per share by a low double-digit percentage. The core tax rate is expected to be 18–22%.

Why Pipeline Depth Matters

Pharmaceutical companies rely on a steady flow of new medicines to replace products as patents expire. AstraZeneca's breadth across therapy areas and its number of late-stage programmes help it plan for the next decade while continuing to serve patients with existing medicines. The company has also highlighted its commitment to sustainability, including its Ambition Zero Carbon programme, which targets reductions in emissions across its operations and value chain. Access to medicines, partnerships with health systems and Investment in education for healthcare professionals also form part of its approach to long-term value creation.

Medicines and Therapy Areas

The group's portfolio includes widely used medicines such as Tagrisso and Imfinzi in oncology and Farxiga in cardiovascular, renal and metabolic disease. Newer launches and combinations are designed to extend the reach of these franchises into earlier stages of disease and wider patient groups. Respiratory and immunology products, together with vaccines and immune therapies, add further diversity.

Investment and Innovation

Innovation is the engine of the business. AstraZeneca invests heavily in clinical development, Manufacturing capability and digital tools that help bring medicines to patients more quickly. Its ongoing expansion of manufacturing across several regions is intended to support Supply and resilience as demand for its products grows, and its partnerships with academic and healthcare institutions help extend its scientific reach.

Factors to Monitor

Investors following LSE:AZN may watch upcoming clinical readouts, regulatory decisions, new launches, pricing developments in key markets and delivery against the 2026 guidance.

Conclusion

AstraZeneca Plc rose 0.99% to 14,034.0p today after third-quarter results showing 7% revenue growth, 14% higher nine-month core earnings per share and 12 positive Phase III readouts. Oncology momentum and the pipeline remain the central themes. Future company announcements should provide further detail on operating progress, capital allocation and management priorities.